Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 21:11:2022-5-4.
doi: 10.7573/dic.2022-5-4. eCollection 2022.

Drug costs in context: assessing drug costs in cost-of-illness analyses

T Joseph Mattingly 2nd  1 , Shannon Weathers  1
Affiliations

Drug costs in context: assessing drug costs in cost-of-illness analyses

T Joseph Mattingly 2nd et al. Drugs Context. .

Abstract

Cost-of-illness (COI) studies attempt to measure and describe the costs associated or attributed to a specific disease, but there are several considerations for measuring and interpreting drug costs estimates. The complexity of the pharmaceutical supply chain and contractual relationships between manufacturers, wholesalers, pharmacies and payers create challenges for researchers attempting to include drug costs in COI analyses. This article aims to provide contextual information for a general audience interested in conducting or evaluating COI studies that may include drug costs and to describe key factors to consider when reviewing drug costs in the peer-reviewed literature.

Keywords: burden-of-illness; cost-of-illness; drug costs; pharmacoeconomics.

PubMed Disclaimer

Conflict of interest statement

Disclosure and potential conflicts of interest: TJM reports consultant fees from the Arnold Foundation and PhRMA, all unrelated to this review. TJM also reports research grant support from PhRMA, the Patient-Centered Outcomes Research Institute, and the Food and Drug Administration unrelated to this review. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at: https://www.drugsincontext.com/wp-content/uploads/2022/06/dic.2022-5-4-COI.pdf

Figures

Figure 1
Figure 1
Drug pricing terms along pharmaceutical supply chain with added payer complexity.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Emanuel EJ. When is the price of a drug unjust? The average lifetime earnings standard. Health Aff. 2019;38(4):604–612. doi: 10.1377/hlthaff.2018.05052. - DOI - PubMed
    1. World Health Organization. WHO Guideline on Country Pharmaceutical Pricing Policies. WHO Document Production Services; 2015. [Accessed July 11, 2022]. https://apps.who.int/iris/handle/10665/335692 . - PubMed
    1. Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses. J Am Med Assoc. 2016;316(10):1093–1103. doi: 10.1001/jama.2016.12195. - DOI - PubMed
    1. Neumann PJ, Willke RJ, Garrison LP. A health economics approach to US value assessment frameworks – Introduction: An ISPOR Special Task Force Report [1] Value Health. 2018;21(2):119–123. doi: 10.1016/j.jval.2017.12.012. - DOI - PubMed
    1. Levy J, Rosenberg M, Vanness D. A transparent and consistent approach to assess US outpatient drug costs for use in cost-effectiveness analyses. Value Health. 2018;21(6):677–684. doi: 10.1016/j.jval.2017.06.013. - DOI - PMC - PubMed